Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
PTGX
#1031
Protagonist Therapeutics, Inc
92.080
0
+6.88%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+6.88%
Changement Mensuel
+11.68%
Evolution sur 6 mois
+22.56%
Changement Annuel
+22.56%
Clôture Précédente
86.150
0
Open
92.210
0
Bid
Ask
Low
92.080
0
High
92.220
0
Volume
152
Marchés
Actions des Marchés US
Soins de Santé
PTGX
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
43.81 M
48.41 M
51.28 M
58.27 M
61.38 M
63.81 M
—
Valuation ratios
Enterprise value
765.82 M
1.53 B
427 M
1.18 B
2.27 B
5.44 B
15.61 B
Price to earnings ratio
—
—
-4.15
-16.85
9.13
-42.6
197.31
Price to sales ratio
—
—
19.89
22.16
5.78
120.66
173.34
Price to cash flow ratio
—
—
4.89
18.93
13.64
96.28
256.13
Price to book ratio
—
—
2.45
3.95
3.72
9.03
13.23
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.2
0.36
0.51
0.22
0.37
0.19
0.19
Return on equity %
0.24
0.42
0.59
0.23
0.41
0.21
0.2
Return on invested capital %
881.2
2 568.99
5 504.26
6 840.28
655.36
311.93
459.71
Gross margin %
100
100
100
100
100
100
400
Operating margin %
72.17 K
460.01
494.24
156.09
58.2
343.63
2 488.48
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
73.99 K
458.94
479.26
131.59
63.34
282.83
2 099.78
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
7.84
7.74
7.8
16.71
12.48
12.71
59.98
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0.08
0.09
0.2
0.79
0.07
0.06
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.03
—
—
—
—
—
—
Long term debt to total equity ratio
0.04
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
2.2
1.24
2.83
0.91
0.93
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
4.84
6.02
6.44
8.92
36.06
Net current asset value per share
—
—
4.96
6.26
9.09
9.09
37.39
Tangible book value per share
—
—
4.4
5.93
10.38
9.67
41.25
Working capital per share
—
—
4.32
5.89
8.36
8.37
34.85
Book value per share
—
—
4.4
5.93
10.38
9.67
41.25
Nouvelles
Le BPA de Protagonist Therapeutics a manqué les attentes de 0,35$, le CA en dessous des prévisions
Protagonist Therapeutics earnings missed by $0.35, revenue fell short of estimates
Citizens relève l’objectif de cours de Protagonist Therapeutics
Citizens raises Protagonist Therapeutics stock price target on drug approvals
Le directeur Williams de Protagonist Therapeutics vend pour 1,48 million de dollars d’actions
Protagonist Therapeutics director Williams sells $1.48 million in shares
Un administrateur de Protagonist Therapeutics vend des actions pour 1,67 million de dollars
Protagonist Therapeutics director sells $1.67 million in shares
Les meilleures actions biotechnologiques à surveiller en 2026, selon Truist
Top Biotech Stocks to Watch in 2026, According to Truist
Objectif de cours de Protagonist Therapeutics relevé à 117$ contre 80$ par H.C. Wainwright
Protagonist Therapeutics stock price target raised to $117 from $80 at H.C. Wainwright